As originally reported in Global Data, the FDA has just given the final approval for a treatment options for pulmonary arterial hypertension (PAH) called ‘Bosentan.’
Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension is a rare disease due to high blood pressure. Because the patient’s arteries in the lungs are blocked or less efficient, the blood must work harder to pump oxygen through the body and reach the organs. Symptoms include shortness of breath, fatigue, fainting, dizziness, chest pain, and swelling. The disease is chronic and progressive, so this disequilibrium wears out the heart over time, which often eventually fails. The disease mainly effects women, and can be inherited or due a number of health related issues such as lung, liver or heart diseases, HIV, or sicklecell or autoimmune disorders. The disease has therapies that slow the onset of the symptoms, but no cure.
The new drug bosentan is administered to improve patients mobility and exercise abilities, as well as to delay the diseases progressions. The drug blocks endothelin, a natural substance from the body which makes blood vessels contract. This medication frees up some of the issues related to blood flow. The tablet, created by Alembic Pharmaceuticals Limited, has been in review for many years in order to measure long term effects.
